Novo Nordisk looks to shake up diabetes market with new pill-based treatment

Novo Nordisk has submitted an approval application for a new diabetes pill to the FDA.

Like other diabetes treatments, the new drug is part of a class of blockbuster GLP-1 diabetes medications. But other treatments have to be administered via injected — and for the first time, Novo Nordisk’s drug would offer diabetes patients a once-daily pill. 

Novo Nordisk is banking on the approval of its new treatment to reinvigorate its diabetes portfolio, which will face new generics competition in a few years. 

The treatment received a priority review voucher from the FDA, which could shorten the review time to six months.

Read the full Reuters report.